NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

RecruitingN/A

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Interventions: Registration into the STREAM platform

Countries: Germany, Italy, Lithuania, Poland, Romania, Spain

This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites

Eligibility overview

Sex: ALL

Age: 6 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with AML diagnosis according to WHO2022 or ICC2022
* Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria
* Participant or his/her legal representative is willing and able to give informed consent for participation in the study

Exclusion Criteria:

* Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.

Locations (40)

Aachen, Germany
Greifswald, Germany
Halle, Germany
Rostock, Germany
Bologna, BO, Italy
Brindisi, BR, Italy
Brescia, BS, Italy
Cuneo, CN, Italy
Como, CO, Italy
Cremona, CR, Italy
Ferrara, FE, Italy
Genova, GE, Italy
Milan, MI, Italy
Milan, MI, Italy
Palermo, PA, Italy
Pescara, PE, Italy
Perugia, PG, Italy
Ravenna, RA, Italy
Roma, RM, Italy
Roma, RM, Italy
Roma, RM, Italy
Roma, RM, Italy
Rimini, RN, Italy
Salerno, SA, Italy
Torino, TO, Italy
Torino, TO, Italy
Castelfranco Veneto, TV, Italy
Busto Arsizio, VA, Italy
Ancona, Italy
Florence, Italy
+ 10 more on CT.gov